Ethypharm has signed an exclusive licence agreement with Clever Leaves for the sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. For Ethypharm, this is a further step to become a leading and trusted provider of medical cannabis products in Europe.
This agreement expands the Ethypharm Group’s offering in its core therapeutic area of the Central Nervous System and confirms its commitment to support patients suffering with chronic pain. “Working with physicians and pharmacists to improve people’s lives is one of Ethypharm’s daily ambitions. Today, providing medical cannabis will answer a clear unmet medical need for patients who are not relieved with current treatments. Partnerships are part of Ethypharm’s DNA. We always look for the optimal partner in any country or region of the world. This collaboration on medical cannabis with Clever Leaves is a good example of how Ethypharm has developed new ways to provide patients with the medical treatment care they need.” said Bertrand Deluard, CEO of Ethypharm.
Clever Leaves, a well recognised cannabis company, will manufacture and supply EU-GMP certified medical cannabis extracts sourced from their facilities in Colombia. The finished products will be marketed and distributed as an Ethypharm branded product portfolio in Germany by its local subsidiary in the 2nd half of 2021. The portfolio include high-CBD, high-THC, and balanced CBD-THC formulations aiming at the symptomatic treatment of neurological diseases as well as chronic pain in palliative settings.
“This partnership with Ethypharm, an established European pharmaceutical company, advances our goal of providing market-leading medical cannabis products to patients. Clever Leaves’ focus on highquality EU-GMP production and international supply chain has positioned us to develop, produce and ship products to endmarkets that will have significant impact on patients’ treatments”, said Kyle Detwiler, CEO of Clever Leaves.
Germany is the second European market after France where the Ethypharm Group offers medical cannabis. Last January, Ethypharm was selected by the French health agency (National Agency for the Safety of Medicines and Health Products - ANSM) to provide medical cannabis products for the first ever French medical cannabis pilot program.
For more information:
+33 (0)1 41 12 17 20